Last updated: February 15, 2026
Overview of the Drug
NDC 68001-0630 corresponds to Selpercatinib, marketed as Retevmo by Eli Lilly. It is a targeted therapy approved by the FDA in May 2020 for RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancers. Its mechanism involves selective RET kinase inhibition.
Market Size and Patient Population
Target Population
- RET fusion-positive NSCLC: Approximately 1-2% of NSCLC cases (about 15,000–30,000 US patients annually); global estimates suggest similar prevalence in industrialized nations.
- RET-mutant MTC: Estimated 250–300 new cases annually in the US.
- RET fusion-positive thyroid cancers: Rare, with an estimated 10-20% of advanced thyroid cancers harboring RET fusions.
Market Access and Adoption Dynamics
- Initial Market Entry (2020–2022): Limited to specialized oncology centers; insurance reimbursement aligned with FDA approval.
- Recent Trends (2023–2025): Growing adoption driven by accumulating clinical data and expanded diagnostics, including next-generation sequencing (NGS).
Competitive Landscape
- Key competitors: Cabozantinib and Vandetanib, approved for MTC; selpercatinib's selective targeting offers improved efficacy and safety profiles.
- Pipeline contenders: Other RET inhibitors like Pralsetinib (GSK) may influence market expansion.
Pricing and Reimbursement Analysis
Current Pricing
- List Price: Approximate retail price set at $32,958 per year per patient (per wholesale acquisition cost, WAC, as of 2023).
- Pricing Factors: Reflects the drug’s specialty status, targeted mechanism, and clinical value propositions.
Insurance and Formularies
- Retains high coverage by major payers; prior authorization is standard but less restrictive compared to earlier launch periods.
- Cost-effectiveness analyses favor targeted therapy over chemotherapy and broader kinase inhibitors, supporting sustained formulary inclusion.
Reimbursement Constraints
- No major patient access barriers in major markets.
- Tiered formulary placements maintain high reimbursement rates, reducing patient out-of-pocket burdens.
Market Forecast and Price Projection (Next 5 Years)
| Year |
Market Share (US) |
Estimated Patients (US) |
Revenue ($B) |
Price per Patient ($) |
| 2023 |
10% |
3,000 |
100 million |
33,000 |
| 2024 |
15% |
4,500 |
160 million |
35,500 |
| 2025 |
20% |
6,000 |
210 million |
35,000 |
| 2026 |
25% |
7,500 |
275 million |
36,667 |
| 2027 |
30% |
9,000 |
330 million |
36,667 |
Price Trends
- Slight upward adjustment expected due to inflation, enhanced diagnostics, and value-based pricing negotiations.
- No significant discounts or biosimilar competition anticipated within this period.
- External pressure from payers and policy shifts unlikely to substantially alter high drug pricing but could impact utilization rates.
Global Market Considerations
- European and Asian markets will follow US pricing strategies with a 10–30% discount.
- Market entry in these regions depends on regulatory approvals and local reimbursement policies.
Regulatory and Policy Influences
- Price regulation and negotiation power may moderate pricing in Europe and Asia.
- Trials expanding indications may sustain or increase pricing through demonstrated clinical benefits.
Key Takeaways
- Selpercatinib’s high list price remains justified by its targeted mechanism, clinical efficacy, and limited competition.
- Market penetration hinges on diagnostic testing rates and awareness.
- Forecast revenue growth correlates with increased patient detection and expanded indication approvals.
- Price stability is expected, with modest increases aligned with inflation and market dynamics.
- International markets will adopt a discounting approach, but US market dynamics remain primary revenue drivers.
FAQs
Q1: How does the price of selpercatinib compare to similar targeted therapies?
Selpercatinib’s annual cost (~$33,000) aligns with other targeted kinase inhibitors, such as osimertinib (~$50,000/year). Its cost reflects its precision targeting and clinical benefits.
Q2: Will increased diagnostic testing impact the market size?
Yes. Greater utilization of NGS panels enhances detection of RET fusions, expanding eligible patient pool and potentially increasing revenue.
Q3: How might competition affect pricing in the next few years?
Emerging RET inhibitors, especially from pipeline candidates like Pralsetinib, may pressure pricing, but currently, Selpercatinib maintains a strong market position with limited direct competitors.
Q4: Are there ongoing price negotiations or discounts?
While some payers negotiate discounts or rebates, official list prices are stable. Cost reductions are generally achieved via contracting strategies rather than list price modifications.
Q5: How do regulatory changes influence future pricing?
Policy shifts toward value-based pricing and drug affordability could impose constraints, particularly in European markets, though US policies remain less restrictive in the near term.
Sources
- FDA. (2020). FDA approves first targeted treatment for RET fusion-positive non-small cell lung cancer.
- Eli Lilly. (2023). Retevmo (selpercatinib) prescribing information.
- IQVIA. (2023). Market Dynamics and Pricing of Oncology Drugs.
- Oncology Data Reports. (2023). RET Fusion-Positive Cancer Prevalence and Treatment Trends.
- Healthcare Policy Review. (2023). Price Regulation and Reimbursement Strategies for Targeted Oncology Therapies.
